Navicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors).

货号（Catalog No.）

CSD00427

通用名INN

Navicixizumab

纯度(Purity)

>95%

浓度( Concentration)

1mg/ml

Formulation

PBS buffer pH7.5

Source

CHO cells

内毒素(Endotoxin level)

Please contact with the lab for this information.

产品描述(Description)

Navicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors).

别名(Alternative names)

OMP-305B83

靶点;物种(Specificity target name;species)

DLL4/VEGFA[Homo sapiens]

种类(Species)

Chimeric,Humanized

受体鉴定(Receptor identification)

IgG2-kappa